Crohn's Disease Clinical Trials

A listing of Crohn's Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 85 clinical trials
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease.

crohn's disease
abdominal pain
remission
  • 992 views
  • 16 Sep, 2022
  • 482 locations
Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.

corticosteroids
abdominal pain
crohn's disease
endoscopy
immunomodulators
  • 550 views
  • 16 Sep, 2022
  • 354 locations
Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.

corticosteroids
abdominal pain
crohn's disease
endoscopy
immunomodulators
  • 918 views
  • 20 Sep, 2022
  • 387 locations
A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (GALAXI)

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of guselkumab in participants with Crohn's disease

colitis
ileocolitis
ileitis
abdominal pain
crohn's disease
  • 861 views
  • 21 Sep, 2022
  • 492 locations
A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn's Disease (CULTIVATE)

active Crohn's disease (CD) who are refractory or intolerant to at least 1 of the current therapies for CD (ie, corticosteroids, immunosuppressants, or biologics). The overall duration of this study is

corticosteroids
mercaptopurine
adalimumab
tumor necrosis factor
tumor necrosis factor alpha
  • 207 views
  • 20 Sep, 2022
  • 323 locations
A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy

Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe Crohn's disease will be treated with

colitis
enteral nutrition
corticosteroids
mercaptopurine
adalimumab
  • 0 views
  • 14 Sep, 2022
  • 41 locations
A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BI 706321 Orally Administered for 12 Weeks in Patients With Crohn's Disease (CD) Receiving Ustekinumab Induction Treatment

This study is open to adults, aged 18-75 years, with moderate to severe Crohn's disease. The purpose of this study is to find out whether BI 706321 combined with ustekinumab helps people

prednisone
corticosteroids
ileitis
mercaptopurine
budesonide
  • 1 views
  • 17 Sep, 2022
  • 34 locations
  • 0 views
  • 20 Sep, 2022
  • 3 locations
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Crohn's Disease (CD): AIM-CD (AIM-CD)

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. CD may cause tiredness, loose stools with or without bleeding, abdominal pain, weight

vedolizumab
adalimumab
crohn's disease
ileal disease
mucosal inflammation
  • 19 views
  • 23 Sep, 2022
  • 120 locations
  • 0 views
  • 21 Sep, 2022
  • 21 locations